We attract distinguished and experienced industry professionals.

Our Scientific Advisory Board (SAB) works closely with the M6P Therapeutics’ leadership team to further advance research and development of the company’s innovative pipeline of lysosomal storage disorders (LSDs). By combining the substantial expertise of the SAB with the expertise of the company’s internal R&D team in enzyme replacement therapies and gene therapies, M6P Therapeutics is well positioned to rapidly advance its deep pipeline of LSD programs.


Stuart Kornfeld

Washington University. Co-Founder, M6P Tx & Chair, SAB


Nancy Dahms

Medical College of Wisconsin


Gregory Enns

Stanford School of Medicine


Mark Sands

Washington University


Anna Tylki-Szymanska

Children's Memorial Health Institute, Warsaw, Poland


Raymond Wang

University of California, Irvine School of Medicine